Vator Securities successfully completes advisory mission for Biovica
Vator Securities, a securities company specializing in financial advisory services for fast-growing companies, today announced the completion of a capital raise in an oversubscribed new share issue of SEK 30 million for Biovica International AB.
Read More
Vator Securities successfully completes advisory mission for IRRAS
Vator Securities today announced the completion of a SEK 91.2 million capital raise for IRRAS AB. IRRAS AB is a commercial medical technology company that develops and sells a groundbreaking pump and catheter system for the treatment of cerebral hemorrhage.
Read More
Immunovia’s new share issue subscribed to a value of SEK 305 million
The rights issue of Immunovia AB (publ) (“Immunovia” or ” the Company”) for the Company’s listing on Nasdaq First North was subscribed to SEK 305 million, which corresponds to a subscription ratio of approximately 500 percent.
Read More
Vator Securities successfully completes advisory mission for Vikingaliv
Vator Securities acted as exclusive financial advisor for Vikingaliv and assisted with obtaining both bank financing and share capital.
Read More
Vator Securities successfully completes advisory mission for Immunovia
Immunovia AB is a Swedish molecular diagnostics company that has developed what can become the world’s first robust test for early diagnosis of pancreatic cancer, which is the fourth deadliest cancer form in the world.
Read More
Vator Securities successfully completes advisory mission for IRRAS
IRRAS has developed a unique pump and catheter system for efficient drainage of fluids from the body and for local administration of drugs in the body.
Read More
Vator Securities successfully completes advisory mission for Bio-Works Technologies
Bio-Works is a biotechnology company that develops, produces and sells innovative separation media products based on agarose to purify proteins, peptides and other biomolecules.
Read More